FI106466B - Förfarande för framställning av terapeutiskt användbara difluorstatonanaloger - Google Patents
Förfarande för framställning av terapeutiskt användbara difluorstatonanaloger Download PDFInfo
- Publication number
- FI106466B FI106466B FI932997A FI932997A FI106466B FI 106466 B FI106466 B FI 106466B FI 932997 A FI932997 A FI 932997A FI 932997 A FI932997 A FI 932997A FI 106466 B FI106466 B FI 106466B
- Authority
- FI
- Finland
- Prior art keywords
- benzyloxy
- difluoro
- amino
- phenyl
- ethyl acetate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (5)
1. Förfarande för framställning av terapeutiskt användbara difluorstatonanaloger med formeln (I) samt far-5 maceutiskt godtagbara salter därav, P2 Pl r Ιη I R, CNHCH CNHCHC-CF,C-NR,R, (t) 1. ii il II il 56 0 0 0 0 10 x i vilken formel x är noll eller ett, Pi är Q eller B, varvid B är 15 0-0^-(0) Q är (CH2>— 4TI0;c,ji' 20 P2 är Cx-6~alkyl, cyklopentyl eller cyklohexyl, Rx är bensyloxi, soin eventuellt är substituerad ... med en nitrogrupp; Ci-6-alkoxi, 2-isokinolinyl, PDL, där > « > 9 . PDL är -(CH2)a“2-, -3- eller 4-pyridyl, varvid a = 1 - 3,
25 R5 är H, Ci-6-alkyl, OH, Ci-6-alkoxi, —i^^j) , där d = 1 eller
2, CH2Si (CH3) 2 (R3) r där R3 är Ci~C4-alkyl; PDL, -N- (CH2) 2-0-CH2CH2, —(Ci_6-alkylen>-OR4, där R4 är Ci~C4- 1_ 1 30 alkyl; eller -CH(Y)(Z), varvid Y är Ci-6-alkyl, och Z är CHO, r6 betecknar samma som R5, förutsatt, att Rö är annat än H, da R5 är H, och da R5 och R6 tillsammans med den 106466 kväveatom, till vilken de är bundna, bildar en heterocyk-lisk enhet med formlerna: -N(CH2)2OCH2CH2
5 I-1 (c) (d) kännetecknat därav, att en förening med forme In 10 P 2 p, r In I1 R, CNHCH CNHCHCCF7C-NR,.R,; Il II I 11 56 o o OH O X 15 där Ri, P2, Pi, R5 och R6 är ovan definierade, oxideras, och de sä erhällna föreningarna med formeln (I) eventuellt om-vandlas tili ett farmaceutiskt godtagbart sait därav. 20 2. Förfarande enligt patentkrav 1, känne tecknat därav, att man framställer en förening med formeln (I), där x ä ett.
3. Förfarande enligt patentkrav 2, kanne-t e c k n a t därav, att man framställer en förening med 25 formeln (I) , där Pi är B.
4. Förfarande enligt patentkrav 1, kännetecknat därav, att man framställer en förening med formeln (I), där Pi är Q.
5. Förfarande enligt patentkrav 1, k ä n n e -30tecknat därav, att man framställer N-[4-(N- S bensyloxikarbonyl-L-valyl)amino-2,2-difluor-l, 3-dioxo-5-(4-bensyloxi)fenylpentyl]-(O-bensyl)-D-valinol. ♦ ·
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91400005 | 1991-01-02 | ||
EP91400005 | 1991-01-02 | ||
PCT/US1991/009741 WO1992012123A1 (en) | 1991-01-02 | 1991-12-20 | Anti-viral compounds |
US9109741 | 1991-12-20 | ||
US78809897 | 1997-01-23 | ||
US08/788,098 US5716973A (en) | 1991-01-02 | 1997-01-23 | Anti-viral compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
FI932997A0 FI932997A0 (fi) | 1993-06-29 |
FI932997A FI932997A (fi) | 1993-06-29 |
FI106466B true FI106466B (sv) | 2001-02-15 |
Family
ID=26129945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI932997A FI106466B (sv) | 1991-01-02 | 1993-06-29 | Förfarande för framställning av terapeutiskt användbara difluorstatonanaloger |
Country Status (19)
Country | Link |
---|---|
US (1) | US5716973A (sv) |
EP (1) | EP0565631B1 (sv) |
JP (1) | JP3198416B2 (sv) |
AT (1) | ATE143025T1 (sv) |
AU (1) | AU649766B2 (sv) |
CA (1) | CA2098020C (sv) |
DE (1) | DE69122266T2 (sv) |
DK (1) | DK0565631T3 (sv) |
ES (1) | ES2094344T3 (sv) |
FI (1) | FI106466B (sv) |
GR (1) | GR3021988T3 (sv) |
HU (1) | HU210647B (sv) |
IE (1) | IE75381B1 (sv) |
IL (1) | IL100477A (sv) |
NO (1) | NO180334C (sv) |
NZ (1) | NZ241099A (sv) |
PT (1) | PT99961B (sv) |
WO (1) | WO1992012123A1 (sv) |
ZA (1) | ZA9110141B (sv) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ249789A (en) * | 1992-03-11 | 1997-07-27 | Narhex Ltd | Hydrazine, carbazate and 1,2-diazacyclic derivatives and pharmaceutical compositions |
US5888992A (en) * | 1992-03-11 | 1999-03-30 | Narhex Limited | Polar substituted hydrocarbons |
DE69333270T2 (de) | 1992-03-11 | 2004-08-05 | Narhex Ltd. | Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen |
US6071895A (en) * | 1992-03-11 | 2000-06-06 | Narhex Limited | Polar-substituted hydrocarbons |
US5559256A (en) * | 1992-07-20 | 1996-09-24 | E. R. Squibb & Sons, Inc. | Aminediol protease inhibitors |
GB9303518D0 (en) * | 1993-02-22 | 1993-04-07 | Merrell Dow Pharma | Combinations of retroviral inhibitors |
US5939430A (en) * | 1993-02-22 | 1999-08-17 | Merrell Pharmaceuticals Inc. | Combinations of retroviral inhibitors |
ES2152982T3 (es) * | 1993-07-08 | 2001-02-16 | Merrell Pharma Inc | Analogos de la difluoroestatona. |
ES2133573T3 (es) * | 1993-09-09 | 1999-09-16 | Merrell Pharma Inc | Analogos antiviricos de difluoro estatone. |
IL110898A0 (en) * | 1993-09-10 | 1994-11-28 | Narhex Australia Pty Ltd | Polar-substituted hydrocarbons |
US5977074A (en) * | 1993-10-01 | 1999-11-02 | Merrell Pharmaceuticals, Inc. | Inhibitors of β-amyloid protein production |
ATE198602T1 (de) * | 1994-02-04 | 2001-01-15 | Merrell Pharma Inc | Makrocyclische difluorostatonderivate als antivirale mittel |
EP0773926A1 (en) * | 1994-07-15 | 1997-05-21 | Merrell Pharmaceuticals Inc. | Difluorostatone antiviral agents |
US6114380A (en) * | 1995-12-18 | 2000-09-05 | Merrell Pharmaceuticals Inc. | Difluoro statone analogs |
NZ530051A (en) | 2001-06-12 | 2006-12-22 | Wellstat Therapeutics Corp | Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1171103A (en) * | 1966-03-24 | 1969-11-19 | Gas Council | Hydrogenation of Hydrocarbons. |
US5066643A (en) * | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
CH672792A5 (sv) * | 1985-02-19 | 1989-12-29 | Sandoz Ag | |
WO1986006379A1 (en) * | 1985-04-19 | 1986-11-06 | The Upjohn Company | Dihalo-statine substituted renin inhibitors |
GB8619182D0 (en) * | 1986-08-06 | 1986-09-17 | Sandoz Ltd | Peptides & derivatives |
NZ223148A (en) * | 1987-01-16 | 1989-10-27 | Merrell Dow Pharma | Peptide derivatives having peptidase inhibition activity |
FR2614533A1 (fr) * | 1987-04-23 | 1988-11-04 | Sandoz Sa | Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments |
FR2624513A1 (fr) * | 1987-12-15 | 1989-06-16 | Sandoz Sa | Peptides contenant du silicium, leur preparation et leur utilisation comme medicaments |
HUT58764A (en) * | 1988-07-08 | 1992-03-30 | Smithkline Beckman Corp | Process for producing peptides, pharmaceutical compositions containing them and amino-acid intermediates |
IL90872A0 (en) * | 1988-07-08 | 1990-02-09 | Smithkline Beckman Corp | Retroviral protease binding peptides |
CA2010531A1 (en) * | 1989-03-06 | 1990-09-06 | Werner Neidhart | Amino acid derivatives |
US5151438A (en) * | 1989-05-23 | 1992-09-29 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5559140A (en) * | 1991-01-02 | 1996-09-24 | Merrell Pharmaceuticals Inc. | Difluoro statone analogs |
EP0632808A1 (en) * | 1992-03-25 | 1995-01-11 | Pfizer Limited | Antiviral peptides |
ATE199545T1 (de) * | 1992-05-21 | 2001-03-15 | Monsanto Co | Inhibitoren retroviraler proteasen |
-
1991
- 1991-12-20 CA CA002098020A patent/CA2098020C/en not_active Expired - Fee Related
- 1991-12-20 ES ES92904336T patent/ES2094344T3/es not_active Expired - Lifetime
- 1991-12-20 NZ NZ241099A patent/NZ241099A/xx unknown
- 1991-12-20 AU AU91790/91A patent/AU649766B2/en not_active Ceased
- 1991-12-20 HU HU9301918A patent/HU210647B/hu not_active IP Right Cessation
- 1991-12-20 WO PCT/US1991/009741 patent/WO1992012123A1/en active IP Right Grant
- 1991-12-20 DK DK92904336.2T patent/DK0565631T3/da active
- 1991-12-20 EP EP92904336A patent/EP0565631B1/en not_active Expired - Lifetime
- 1991-12-20 AT AT92904336T patent/ATE143025T1/de not_active IP Right Cessation
- 1991-12-20 JP JP50439692A patent/JP3198416B2/ja not_active Expired - Lifetime
- 1991-12-20 DE DE69122266T patent/DE69122266T2/de not_active Expired - Lifetime
- 1991-12-23 IL IL10047791A patent/IL100477A/en not_active IP Right Cessation
- 1991-12-23 ZA ZA9110141A patent/ZA9110141B/xx unknown
- 1991-12-31 PT PT99961A patent/PT99961B/pt not_active IP Right Cessation
- 1991-12-31 IE IE458091A patent/IE75381B1/en not_active IP Right Cessation
-
1993
- 1993-06-29 NO NO932377A patent/NO180334C/no not_active IP Right Cessation
- 1993-06-29 FI FI932997A patent/FI106466B/sv active
-
1996
- 1996-12-11 GR GR960403424T patent/GR3021988T3/el unknown
-
1997
- 1997-01-23 US US08/788,098 patent/US5716973A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
IE75381B1 (en) | 1997-09-10 |
ZA9110141B (en) | 1992-10-28 |
HUT65739A (en) | 1994-07-28 |
JPH07502255A (ja) | 1995-03-09 |
AU649766B2 (en) | 1994-06-02 |
GR3021988T3 (en) | 1997-03-31 |
PT99961B (pt) | 1999-06-30 |
JP3198416B2 (ja) | 2001-08-13 |
AU9179091A (en) | 1992-08-17 |
NO180334C (no) | 1997-04-02 |
ATE143025T1 (de) | 1996-10-15 |
IL100477A (en) | 1996-07-23 |
ES2094344T3 (es) | 1997-01-16 |
CA2098020A1 (en) | 1992-07-03 |
DE69122266T2 (de) | 1997-03-27 |
US5716973A (en) | 1998-02-10 |
DE69122266D1 (de) | 1996-10-24 |
HU9301918D0 (en) | 1993-12-28 |
FI932997A0 (fi) | 1993-06-29 |
EP0565631B1 (en) | 1996-09-18 |
PT99961A (pt) | 1993-01-29 |
DK0565631T3 (da) | 1996-10-07 |
HU210647B (en) | 1995-06-28 |
IE914580A1 (en) | 1992-07-15 |
EP0565631A1 (en) | 1993-10-20 |
NO932377L (no) | 1993-06-29 |
FI932997A (fi) | 1993-06-29 |
NO932377D0 (no) | 1993-06-29 |
CA2098020C (en) | 2003-10-21 |
NZ241099A (en) | 1994-08-26 |
NO180334B (no) | 1996-12-23 |
WO1992012123A1 (en) | 1992-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI106466B (sv) | Förfarande för framställning av terapeutiskt användbara difluorstatonanaloger | |
EP0337714A3 (en) | Hiv protease inhibitors useful for the treatment of aids | |
JPH0741497A (ja) | レトロ等立体性ジペプチド、その製造方法及び薬剤におけるレニン阻害剤としてのその使用 | |
AU672867B2 (en) | 4-amino-3-hydroxycarboxylic acid and their use as anitvirals | |
US5559140A (en) | Difluoro statone analogs | |
FI120389B (sv) | Förfarande för framställning av nya terapeutiskt användbara difluorstatonanaloger | |
AU683927B2 (en) | Difluoro statone antiviral analogs | |
KR100367379B1 (ko) | 항바이러스제로유용한마크로시클릭디플루오로스타톤유도체 | |
US6114380A (en) | Difluoro statone analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Transfer of assignment of patent |
Owner name: AVENTIS INC. Free format text: AVENTIS INC. |